<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the multicentric trial LALA87 was to test the efficacy of different postremission therapies in adults (15 to 60 year olds) with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="1" pm="."><plain>An immunologic subclassification based on surface marker expression was proposed </plain></SENT>
<SENT sid="2" pm="."><plain>Among the 562 tested patients, 511 were assigned either to the B lineage (361 cases, 63%) or to the T lineage (150 cases, 26%) </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> were significantly associated with male sex, age less than 35 years, <z:e sem="disease" ids="C0240318" disease_type="Disease or Syndrome" abbrv="">mediastinal mass</z:e>, central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement, high white blood cell count, and low <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In a univariate and multivariate analysis, T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> had a more favorable outcome than B-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> with respective median disease-free survivals (DFSs) of 28 and 14 months (P &lt; .005) </plain></SENT>
<SENT sid="5" pm="."><plain>However, the type of postremission therapy modifies the value of the immunophenotype prognostic factor </plain></SENT>
<SENT sid="6" pm="."><plain>In the chemotherapy arm, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients (26 patients) had a more favorable outcome than <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients (57 patients) (P &lt; .003) </plain></SENT>
<SENT sid="7" pm="."><plain>In the autologous bone marrow transplantation (ABMT) arm, the apparent better outcome of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients (35 T/50 B) did not reach statistical significance (P = .2) and there was no difference in the allogeneic bone marrow transplantation (alloBMT) arm (37 T/71 B: P = .9) </plain></SENT>
<SENT sid="8" pm="."><plain>In the B-cell-lineage <z:hpo ids='HP_0001909'>leukemias</z:hpo>, subclassification by stages and myeloid antigen coexpression (10%) were not associated with different prognosis </plain></SENT>
<SENT sid="9" pm="."><plain>CD10+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> (31 patients) were associated with a better DFS compared with the CD10- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> (73 patients) with respective median DFS, not reached and 18.5 months (P = .04) </plain></SENT>
</text></document>